Commences Phase 2 Trial Of Nnz-2591 In Angelman Syndrome
12/07/2022 06:58
Neuren Pharmaceuticals Ltd NEU.AX :
* NEUREN PHARMACEUTICALS LTD - COMMENCES PHASE 2 TRIAL OF
NNZ-2591
IN ANGELMAN SYNDROME
* NEUREN PHARMACEUTICALS LTD - TOP-LINE RESULTS ARE
ANTICIPATED
FOR H1 2023.
Source text for Eikon: ID:nASX8FYtsP
Further company coverage: NEU.AX
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union